Servier is delighted to welcome Peter Adamson, a globally recognized physician-scientist and executive leader, as our new Global Head of Oncology Clinical Development. In this role, Peter will lead our worldwide team of physicians and clinical scientists and help drive our oncology pipeline forward.  

Peter brings deep expertise across oncology drug development, clinical pharmacology, translational research and mission-driven leadership. A Professor Emeritus at the University of Pennsylvania, he has led Phase 1–3 trials and cross-sector R&D programs across academia, industry and government. 

Prior to joining Servier, Peter served as Global Head of Oncology Development at Sanofi, where he led more than 15 global teams spanning early- and late-stage assets supporting a broad oncology portfolio, including antibody-drug conjugates, cell and immune therapies and cytokines. In this role, he oversaw multiple global approvals and guided business development efforts across the United States, Europe and China.  

Earlier, he led the Children’s Oncology Group as Chair and CEO, launched Project: EveryChild, now the world’s largest ongoing pediatric cancer research initiative, and held leadership roles at Children’s Hospital of Philadelphia, the University of Pennsylvania and the National Cancer Institute.  

Peter was appointed by President Barack Obama to the National Cancer Advisory Board and served on the Cancer Moonshot Blue Ribbon Panel. He has advised more than 15 cancer foundations and played an instrumental role in shaping U.S. childhood cancer policy.  

He earned his MD from Cornell University Medical College and a BA in Chemistry from Wesleyan University. He completed his pediatric residency at the Children’s Hospital of Philadelphia and a fellowship in Pediatric Hematology/Oncology at the National Cancer Institute. 

We look forward to growing under Peter’s leadership and continuing to advance our mission to deliver transformative therapies to patients with cancer.